戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 m that typically observed in CKD-mineral and bone disorder.
2 ty trias of alcohol abuse-depression/anxiety-bone disorder.
3 on metabolism is a hallmark of CKD-metabolic bone disorder.
4 ed by the chronic kidney disease-mineral and bone disorder.
5 enesis of chronic kidney disease mineral and bone disorder.
6 raise suspicions about a possible underlying bone disorder.
7 ntributes to post-transplant CKD mineral and bone disorder.
8 n cherubism, a rare autosomal-dominant human bone disorder.
9 re used globally for the treatment of common bone disorders.
10 of PTH 1-84 and contribute to CKD-associated bone disorders.
11 m can be used to model genetic cartilage and bone disorders.
12 f ALP in blood can indicate liver disease or bone disorders.
13 could lead to new treatments for age-related bone disorders.
14 jor drug target for osteoporosis and related-bone disorders.
15 es with risks for cancer, cardiovascular and bone disorders.
16 with great promise as therapeutic agents for bone disorders.
17 rs was an independent factor associated with bone disorders.
18 t role in the treatment of periodontitis and bone disorders.
19 ts further our knowledge of FGFR3-associated bone disorders.
20 al benefit and render BMT more applicable to bone disorders.
21 te human Opt as a candidate gene for brittle bone disorders.
22  therapeutic target for bone loss in various bone disorders.
23 d paralog of MAN1, an NE component linked to bone disorders.
24 ention, and treatment of pediatric metabolic bone disorders.
25 ct of mechanism-based anabolic therapies for bone disorders.
26  immunologic aspects of the autoinflammatory bone disorders.
27 ht yield novel therapeutics to treat typical bone disorders.
28 r bone remodeling and is altered in multiple bone disorders.
29 ions in CBF genes are found in leukemias and bone disorders.
30  play a pivotal role in diagnosing metabolic bone disorders.
31 , raising new directions in the treatment of bone disorders.
32                                  An adynamic bone disorder (ABD) is an important complication of chro
33 n the Runt domain found in hematopoietic and bone disorders affect its affinity for DNA.
34 rteriosclerosis, vascular calcification, and bone disorders, all of which are also associated with ag
35 of uremic retention solutes, and mineral and bone disorders also contribute to cardiovascular disease
36 tudy revealed a high prevalence of metabolic bone disorders among viral cirrhotic patients.
37 phosphatemia in a mouse model of CKD-mineral bone disorder and alphaKL-null mice.
38 sk factor for periodontitis, an inflammatory bone disorder and the greatest cause of tooth loss in ad
39 d Amy, analogs of which are therapeutics for bone disorders and diabetes, respectively.
40                                     Systemic bone disorders and PAD are frequent in ESRD.
41 phosphatemia in a mouse model of CKD-mineral bone disorder, and it reduced hyperphosphatemia and prev
42 tations in CBF genes are found in leukemias, bone disorders, and gastric cancer.
43 tations in CBF genes are found in leukemias, bone disorders, and gastric cancers.
44 nfections, vitamin D deficiency or metabolic bone disorders, anxiety disorders, and fractures; the in
45               Finally, several cartilage and bone disorders are due to abnormalities in sulfate trans
46                                              Bone disorders are of significant concern due to increas
47                                    Metabolic Bone disorders are well-recognized extrahepatic complica
48          Findings from research into mineral bone disorder associated with CKD (CKD-MBD) could help t
49                  Osteoporosis is a metabolic bone disorder associated with compromised bone strength
50 -Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-beta activit
51                            Osteoporosis is a bone disorder associated with loss of bone mineral densi
52  broad spectrum of conditions that encompass bone disorders associated with alterations of mineral qu
53 sents a summary of recent reports concerning bone disorders associated with disorders of the liver an
54 del, however, is complicated by the adynamic bone disorder; both calcitriol and paricalcitol stimulat
55 hosphonates (NBPs) are taken by millions for bone disorders but may cause serious inflammatory reacti
56 he pathophysiology of many acute and chronic bone disorders, but the specific inflammatory networks t
57 e bone disease' has mainly been considered a bone disorder caused by collagen mutations.
58  hypophosphataemia (XLH) is a rare metabolic bone disorder caused by pathogenic variants in the PHEX
59 reatment of craniosynostosis or other severe bone disorders caused by mutations in FGFRs that current
60 tegies and may inform clinical treatments of bone disorders causes by load-deficiency.
61 esis imperfecta (OI) is an inherited brittle bone disorder characterized by bone fragility and low bo
62 O, MIM 174810) is a rare, autosomal dominant bone disorder characterized by focal areas of increased
63 sease of bone, or "osteitis deformans," is a bone disorder characterized by rapid bone remodeling res
64    Osteopetrosis is a heterogeneous group of bone disorders characterized by the failure of osteoclas
65           Chronic kidney disease-mineral and bone disorder (CKD-MBD) is associated with secondary hyp
66           Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) may be both a cause and a conseq
67           Chronic kidney disease-mineral and bone disorder (CKD-MBD) presents with extra-skeletal cal
68  the term chronic kidney disease-mineral and bone disorder (CKD-MBD) to describe the syndrome of bioc
69 jury model of chronic kidney disease-mineral bone disorder (CKD-MBD), SIK inhibitor treatment stimula
70 of late stage chronic kidney disease-mineral bone disorder (CKD-MBD), specifically the development of
71 atment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
72 r risk and are components of CKD-mineral and bone disorder (CKD-MBD).
73           Chronic kidney disease mineral and bone disorders (CKD-MBD) and vascular calcification are
74 er small molecule leads for the treatment of bone disorders concluded with the discovery of a compoun
75  cancer diagnosis, cancer margin evaluation, bone disorder detection and glucose level determination.
76 anifestations of NF1, including learning and bone disorders emphasize the importance of dissecting th
77                                      Another bone disorder, familial expansile osteolysis (FEO), alth
78                            Heritable fragile bone disorders (FBDs), ranging from multifactorial to ra
79 CKD in this model is associated the adynamic bone disorder form of renal osteodystrophy.
80 y GORAB, the protein mutated in the skin and bone disorder gerodermia osteodysplastica, as a componen
81 ue regeneration and reduce post-implantation bone disorders has been limited.
82 gement of chronic kidney disease-mineral and bone disorders has recently changed.
83 malities in common causes of CKD-mineral and bone disorder have been defined, it is unknown if persis
84 en learned in the monogenic autoinflammatory bone disorders, IL-1 is emerging as an important pathway
85 es, which lead to the development of various bone disorders in both women and men.
86 cs and immunologic basis of autoinflammatory bone disorders including chronic recurrent multifocal os
87 ion changes implicated genes associated with bone disorders, including FBLIM1, IHH, and SCAMP2.
88           Chronic kidney disease-mineral and bone disorder is nearly universal in dialysis-dependent
89  TNF inhibits bone formation in inflammatory bone disorders is by promoting Runx2 proteasomal degrada
90     The chronic kidney disease (CKD)-mineral bone disorder (MBD) is a syndrome recently coined to emb
91               Separate assessment of mineral bone disorder (MBD) parameters including calcium, phosph
92 Paediatric Nephrology (ESPN) CKD-Mineral and Bone Disorder (MBD), Dialysis and Transplantation workin
93                       Anemia and mineral and bone disorders (MBD) are both important and common compl
94 amin D(3) is essential for the prevention of bone disorders, muscle weakness, autoimmune diseases, an
95               There are two primary types of bone disorders observed in patients with end-stage renal
96 own in the human INPPL1-related endochondral bone disorder, opsismodysplasia.
97 e expression to osteoblasts for treatment of bone disorders or tumor metastasis to the skeleton.
98 ), certain types of cancer, and degenerative bone disorders (osteoarthritis).
99 ollagen triple helix, lead to the hereditary bone disorder osteogenesis imperfecta (OI).
100                               The hereditary bone disorder osteogenesis imperfecta is often caused by
101 es in MSCs from individuals with the brittle bone disorder osteogenesis imperfecta, demonstrating suc
102 ple helix results in the dominant hereditary bone disorder osteogenesis imperfecta.
103 wing prevalence of metabolic and age-related bone disorders, our results demonstrate for the first ti
104                                Human genetic bone disorders provide insight into bone regulatory proc
105 tanding the genetic underpinnings of mineral bone disorder related to CKD.
106 flammatory networks that regulate individual bone disorders remain to be elucidated.
107 sent the first five cases of a new recessive bone disorder resulting from null LEPRE1 alleles; its ph
108 ures, gene identification in each 'vanishing bone' disorder should provide unique insights into genet
109 s an established concept in the treatment of bone disorders such as osteoporosis or certain forms of
110 are potential therapies for the treatment of bone disorders such as osteoporosis.
111 e and have been targeted for intervention of bone disorders such as osteoporosis.
112 process, and deregulation can lead to severe bone disorders such as osteoporosis.
113  represent potential therapeutic targets for bone disorders such as osteoporosis.
114 l, bone anabolic agents for the treatment of bone disorders such as osteoporosis.
115 ediator of joint destruction in inflammatory bone disorders, such as RA.
116         Cherubism is a rare autoinflammatory bone disorder that is associated with point mutations in
117 een identified in monogenic autoinflammatory bone disorders that have allowed more detailed dissectio
118                    Newly diagnosed metabolic bone disorders were seen in 58% of the breast cancer pop
119                                              Bone disorders were significantly more frequent in old p
120 sis is the most common age-related metabolic bone disorder, which is characterized by low bone mass a
121 ations of chronic kidney disease-mineral and bone disorder with a special focus on the incidence of f
122 e P392L SQSTM1 mutation in humans, develop a bone disorder with remarkable similarity to PDB.
123 ssure index (ABix) and evaluated mineral and bone disorders with bone histomorphometry.

 
Page Top